Cancer Immunology Project Awards
About this scheme
Applications are accepted from:
- Scientists, clinicians or health care workers from UK universities, medical schools, hospitals and some research institutes.
- The lead applicant (PI) must be an immunologist who should not have a demonstrated track record in cancer research.
- Collaborations with cancer researchers/clinicians are strongly encouraged to deliver the project but are not a mandatory requirement.
If you have a demonstrated track record in cancer, or are a group leader at a CRUK core-funded Institute, you are not eligible to apply for this award as the lead PI, but may act as a co-investigator or collaborator.
The aim of the scheme is to build capacity in cancer immunology; therefore, if you already have a demonstrated track record in cancer research, our other opportunities in discovery research or opportunities for early- and mid-career researchers may be more suitable for your research.
To assess your suitability to apply, please email us with a one-page summary of your proposal, a list of potential collaborators and your CV.
Your proposal should address key questions in the immunology of cancer. Applications can be in any area of immunological research, providing the cancer relevance is clearly articulated in the proposal, including any of the following key areas:
Cellular and molecular immunology: including but not limited to mechanisms of tolerance, the regulation of immune function, the development of memory, the interaction of immune cells with tissues and enhancing the immune system’s ability to detect and destroy cancer.
Inflammation, allergy, transplantation and autoimmunity: how the basic understanding of relevant mechanisms involved could drive forward our understanding of cancer as well as how sensing of endogenous changes in immune homeostasis, such as tissue damage, impacts on the sensing and development of cancers.
Immune response to infection: including but not limited to immunity and disease susceptibility/resistance and the development of adverse infections in response to immune therapy or biological drug intervention.
If you are looking for support for the discovery and development of new biotherapeutics or immunomodulatory agents, explore our opportunities in drug discovery and development.
CRUK-Versus Arthritis Immunology Project Award
We're working with Versus Arthritis to maximise progress in our shared priorities spanning both cancer and musculoskeletal conditions. Joint CRUK-Versus Arthritis Immunology Project Awards will foster collaborations between researchers from both fields, and encourage researchers to share expertise and address questions relevant to both disease areas. Applicants must articulate how their research proposal will bring patient benefit for both diseases.
Examples of proposals relevant to both cancer and arthritis that we particularly welcome are:
- Proposals in the area of immune-metabolism.
- Proposals addressing the mechanisms behind adverse autoimmune events in cancer immunotherapy, such as the exacerbation of inflammatory arthritis.
- Mechanism of action studies that explore opportunities to re-position existing drug strategies that support the treatment of cancer or arthritis.
- Investigations that support the diagnosis, stratification or treatment decisions specific to the management of cancer or arthritis.
If you have a track record in cancer research, you are eligible to apply to the Joint Award as the Lead PI, as long as your proposal addresses questions relevant to both cancer and muscoloskeletal conditions and has a collaborative approach to building links between fields.
The application process, timelines and funding available are the same as for Cancer Immunology Project Awards. Applications will be administered and assessed alongside the Cancer Immunology Project Awards, and successful applications will be jointly funded by both charities.
How to apply to this scheme
- You must email us with a one-page summary of your proposal, a list of potential collaborators and your CV. We advise you do this at least one month before the deadline.
- If your proposal is eligible, we will invite you to make a formal application through our electronic Grants Management System (eGMS)
- Your application will be assessed by international peer review, before review by our Cancer Immunology Expert Review Panel.
- The final funding decision will be made by our Science Committee.
Applications for Cancer Immunology Project Awards are considered twice a year.
9 May 2019
7 November 2019
Before you begin your application
The Science Committee will judge your proposal based on:
- Scientific excellence: all applications must have a strong scientific rationale, as well as appropriate experimental design and statistical analyses, to support the proposed research proposal.
- Cancer relevance: value of the proposed work in advancing the fundamental understanding of cancer or improving how cancer is diagnosed and/or treated.
- Track record: the lead applicant and/or team members should have an excellent track record and potential to produce outstanding results.
- Excellent team and collaborative environment: suitability and feasibility of the Lead Applicant(s) (and supporting roles) to carry out the proposed research with access to the resources and facilities required for the successful fulfilment of the Programme Award. The added value of the proposed collaboration and the individual contributions, as well as the steps taken to ensure an effective collaboration.
- Resources requested: the costs requested in an application should be for the direct costs of the research and be reasonably justified in line with the experimental plans, leveraging existing resources where appropriate.
Cancer Research UK contact details
More opportunities for discovery researchers
We support a broad portfolio of discovery research, including basic biology, genetics and immunology, biomarker discovery and preclinical studies, and engineering and physical sciences applied to cancer. We have a variety of grant funding and other opportunities to accelerate your research.
Andrew Mellor is using funding from our Immunology Project Award to explore the link between dying cells and inflammatory responses that promote cancer development.